T-Knife
5 known investors
T-knife develops engineered T cell therapies designed to treat patients with solid tumors, using proprietary platforms and synthetic biology to enhance T cells. Its lead candidate, TK-6302, targets the PRAME tumor antigen, with a Phase 1 trial planned to begin in 2026.
Founders & leadership
EK
Elisa KiebackinCTO and co-founder
Investors · 5
In the news
Frequently asked questions
- What does T-Knife do?
- T-knife develops engineered T cell therapies designed to treat patients with solid tumors, using proprietary platforms and synthetic biology to enhance T cells. Its lead candidate, TK-6302, targets the PRAME tumor antigen, with a Phase 1 trial planned to begin in 2026.
- Who founded T-Knife?
- T-Knife was founded by Elisa Kieback.
- Who are T-Knife's investors?
- T-Knife's investors include Andera Partners, RA Capital, Sixty Degree Capital, Versant Ventures, Fidelity Investments.